Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis —A Systematic Review and Meta-Analysis

Allogeneic hematopoietic cell transplant (allo-HCT) remains the only potentially curative therapeutic modality for patients with primary or secondary myelofibrosis (MF). However, many patients are considered ineligible for allo-HCT, and transplant-related mortality can be substantial. Data on the efficacy and safety of allo-HCT are mixed and largely derived from retrospective studies. We wanted to synthesize the available evidence on the safety and efficacy of allo-HCT in MF and to identify patient, disease, and transplant characteristics with prognostic impact on outcomes of patients with MF undergoing allo-HCT.

Source: Biology of Blood and Marrow Transplantation - May 27, 2021 Category: Hematology Authors: Jan Philipp Bewersdorf, Amar H. Sheth, Shaurey Vetsa, Alyssa Grimshaw, Smith Giri, Nikolai A. Podoltsev, Lohith Gowda, Roni Tamari, Martin S. Tallman, Raajit K. Rampal, Amer M. Zeidan, Maximilian Stahl Source Type: research